Original Research Article

The incidence of AmpC β-lactamases producing *Klebsiella pneumoniae* subspecies *pneumoniae*

Priyanka Singh*

Department of Microbiology, RKDF Medical College, Bhopal, Madhya Pradesh, India

Received: 24 February 2018
Accepted: 06 March 2018

*Correspondence:
Dr. Priyanka Singh,
E-mail: priyankasingh27031982@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

**ABSTRACT**

**Background:** AmpC β-lactamases in the clinical isolates reduces the therapeutic value of β-lactam-β-lactam inhibitor combinations. If not detected can be disseminated in the hospital environment and pose a serious therapeutic challenge. Hence present study is undertaken to detect the incidence of AmpC β-lactamases producing *Klebsiella pneumoniae* subspecies *pneumoniae* out of total 300 *Klebsiella pneumoniae* subspecies *pneumoniae* isolated from different clinical samples of the patient attending Jawaharlal Nehru Medical College and its hospital in Dept of Microbiology.

**Methods:** Isolates are screened for presumptive AmpC production by testing their susceptibility to Cefoxitin using Kirby-Bauer disk diffusion method. Phenotypic confirmatory tests for detection of AmpC β-lactamases by Modified three dimensional test, Amp C disc test, Amp C disc test with Inhibitor (Boronic Acid) based disc potentiation test.

**Results:** In our present study 75 (25%) *Klebsiella pneumoniae* strains were positive for AmpC β-lactamases production either alone or in combinations with other β-lactamases. 75 strains were positive for AmpC β-lactamase (25%). These 75 strains were further confirmed by E Test.

**Conclusions:** Overproduction of AmpC β-lactamases by mutation is responsible for resistance. If not detected can be pose a serious therapeutic challenge. So, its detection improves the therapeutic outcome in patient care.

**Keywords:** AmpC β-lactamases, DP-Test, ESBL, E-Test, *Klebsiella pneumoniae*

**INTRODUCTION**

**AmpC β-lactamase**

AmpC β-lactamases of *Escherichia coli* was reported to be first bacterial enzyme to destroy Penicillin, although it had not been so named in 1940.1 Mutation with stepwise-enhanced resistance were termed ampA and ampB and a mutation in an amp A strain that resulted in reduced resistance was designated as Amp C. Then it was suggested that AmpC was the structural gene for this enzyme.2 The sequence of amp C gene from *Escherichia coli* was reported in 1981. The ampC β-lactamases differed from the penicillinase type β-lactamases such as TEM -1 but had serine at its active sites.3 In Ambler classification AmpC beta lactamases belongs to class C while in functional classification of Bush Jacoby Mederos Amp C β-lactamases belongs to group 1.4,5

They are active on Penicillin but more active on Cephalosporins and can hydrolyse Cephamycins like Cefoxitin and Cefotetan. Oxyimino cephalosporins such as Ceftazidime, Cefotaxime and Ceftriaxone and monobactams such as Aztreonam and are not inhibited by clavulanic acid, sulbactum and tazobactam. Cloxacillin and Oxacillin are good inhibitors of AmpC β-lactamases. AmpC β-lactamase are found as chromosomally mediated
or plasmid mediated. The chromosomally mediated AmpC β-lactamase are inducible.

Chromosomally mediated AmpC β-lactamase are present in Gram negative bacilli e.g. Pseudomonas aeruginosa, Enterobacter spp, Acinetobacter spp. and Aeromonas spp. etc. Overproduction of their chromosomal AmpC β-lactamases by mutation is responsible for resistance. Plasmid mediated AmpC enzyme e.g. CMY type β-lactamase found in bacterial spp., which naturally lacks chromosomal β-lactamases such as Klebsiella pneumoniae, Proteus mirabilis and Salmonella spp. Plasmid mediated β-lactamases have arisen through transfer of chromosomal AmpC gene into plasmids. Presence of ESBL may be masked by coincident AmpC β-lactamases enzyme.

Aims and objective of the study was to study the incidence of AmpC β-lactamases producing Klebsiella pneumoniae subspecies pneumoniae out of total Klebsiella pneumoniae subspecies pneumoniae isolated from different clinical samples of the patient attending Jawaharlal Nehru Medical College and its hospital (Acharya Vinoba Bhave Rural Hospital), Wardha (MS).

**METHODS**

The present study was conducted in the Department of Microbiology, Jawaharlal Nehru Medical College, Wardha (M.S). The period of study was 1 year from 1.7.2014 to 30.6.2015

**Screening test for AmpC β-lactamase**

1. Isolates are screened for presumptive AmpC production by testing their susceptibility to Cefoxitin using Kirby-Bauer disk diffusion method. All the isolates with inhibition zone diameter of less than 18mm are labelled as screen positive.

2. Phenotypic confirmatory tests for detection of AmpC β-lactamases
   - Modified three dimensional test (M3DT).
   - Amp C disc test.
   - Amp C disc test with Inhibitor (Boronic Acid) based disc potentiation test.

3. Molecular methods for detection and confirmation of AmpC β-lactamase.
   - Polymerase chain reaction (PCR).
   - Nucleotide sequencing analysis of AmpC encoding genes.

**Detection of AmpC β-Lactamases**

For Detection of AmpC β- Lactamases, no satisfactory technique has been established till date as per CLSI guideline. As AmpC β-Lactamases production is mostly plasmid mediated in Enterobacteriaceae and not chromosomally induced, D-zone test cannot be done in case of Klebsiella pneumoniae.

**Screening Test**

The isolates were screened for presumptive AmpC production by testing their susceptibility to Cefoxitin and Cefotetan using Kirby- Bauer disk diffusion method. The inhibition zone sizes were interpreted as per CLSI guideline. All the isolates with an inhibition zone diameter of ≤18mm for Cefoxitin and ≤16mm diameter for Cefotetan respectively were labeled as screen positive.

**Confirmatory Test**

All 300 Klebsiella pneumoniae strains were studied for AmpC β-lactamases production and were confirmed by confirmatory test using Cefoxitin (CX) and Cefoxitin-Cloxacillin (CXX) discs. This test is based on the inhibitory effect of Cloxacillin on AmpC-β-lactamases. The discs containing Cefoxitin and Cefoxitin plus Cloxacillin were put on MH agar plate and the plates were incubated at 35°C for 16-18 hours. An increase in zone size of ≥4mm around the disc Cefoxitin plus Cloxacillin compared to Cefoxitin disc only was considered positive for AmpC production.

AmpC β-Lactamases production was further confirmed by disk potentiation test using Cefazidime / Ceftazidime plus 3-aminophenylboronic acid.

**Disk potentiation test**

All 300 Klebsiella pneumoniae strains were tested by disc potentiation test for AmpC β-lactamases production. An overnight broth culture of test strain was inoculated on Mueller Hinton agar plate with sterile swab. Two Cefazidime disc with center to center distance of 30mm were placed on that inoculated plate. 3- APB solution was added to one of the Cefazidime disc. After overnight incubation at 37°C, an increase in zone size of ≥5mm around the Cefazidime plus 3-APB disc compared to Cefazidime alone was considered as positive for AmpC β-lactamase production.

**Confirmation of AmpC β-lactamase producing strains by E test**

AmpC β-lactamases producing Klebsiella pneumoniae strains were further confirmed by E test (bioMerieux). The E test strip has concentration gradient of Cefoxitin (CN 0.5-32µg/ml) on one half and Cefoxitin-Cloxacillin (CNI 0.5-32µg/ml) on the other half. The AmpC β lactamase E test was done and interpreted as per manufacturer’s instructions manual. In this method lawn culture of test strain (turbidity adjusted to 0.5 Mc Farland Standard) was done on a Mueller Hinton agar plate. With a sterile forceps the E-test strip was placed onto the inoculated plate. After overnight incubation at 37°C, the zone of
Inhibition was read from two halves of the strip. MIC ratio of Cefoxitin/Cefoxitin-Cloxacillin ≥8 or deformation of ellipse or phantom zone present was considered as positive for AmpC β-lactamase production.

RESULTS

Table 1 shows that 75 (25%) Klebsiella pneumoniae strains were positive for AmpC β-lactamases production either alone or in combinations with other β-lactamases. All 300 Klebsiella pneumoniae strains were tested by screening tests and confirmatory tests (CX/CXX and CAZ/CAZ+ 3-APB). The screening tests were done by Kirby-Bauer disc diffusion method using Cefoxitin (CX) and Cefotetan (CTN). Out of 300 Klebsiella pneumoniae strains 91 (30.3%) strains were screen positive by Cefoxitin disc and 101 (33.7%) strains were screen positive by Cefotetan. The Confirmatory tests were done by combined disc method using and Ceftazidime (CAZ) / Ceftazidime plus 3- Aminophenyl boronic acid (CAZ+ 3-APB) Cefoxitin (CX) / Cefoxitin plus Cloxacillin (CXX) and 75 strains were positive for AmpC β-lactamase (25%). These 75 strains were futher confirmed by E Test (CNI). The screening tests were done by Kirby-Bauer disc diffusion method using Cefoxitin (CX) and Cefotetan (CTN). Out of 300 Klebsiella pneumoniae strains 91 (30.3%) strains were screen positive by Cefoxitin disc and 101 (33.7%) strains were screen positive by Cefotetan. The Confirmatory tests were done by combined disc method using and Ceftazidime (CAZ) / Ceftazidime plus 3- Aminophenyl boronic acid (CAZ+ 3-APB) Cefoxitin (CX) / Cefoxitin plus Cloxacillin (CXX) and 75 strains were positive for AmpC β-lactamase (25%). These 75 strains were futher confirmed by E Test (CNI).

Table 1: Detection of AmpC β- lactamases producing Klebsiella pneumoniae strains by different methods (n=300).

| Klebsiella pneumonia | Screening Test | Confirmatory Test |
|----------------------|----------------|-------------------|
| Total AmpC β- lactamases Producers No. | Cefoxitin (CX) No. | Cefoxitin/ Cefoxitin + Cloxacillin (CX/CXX) No. | Cefoxidime / Ceftazidime + 3-Aminophenylboronic acid (CAZ / CAZ + 3-APB) E-Test No. |
| 75 (25%) | 91 (30.3%) | 101 (33.7%) | 75 | 75 |

DISCUSSION

Table 2 shows the incidence of AmpC β-lactamase producing Klebsiella pneumoniae strains reported by various workers. In 2005 Suranjana et al, had reported 13% AmpC β-lactamase producing Klebsiella pneumoniae strains. In the present study total 25% AmpC β-lactamase producing Klebsiella pneumoniae strains were isolated. In present study, 22.2% strains were ESBL and AmpC β-lactamase Co producers. Only few studies have reported both ESBL and AmpC β-lactamase producing Klebsiella pneumoniae strains. In 2010 Mohanty et al, have reported as high as 58.4% ESBL and AmpC β-lactamase producing strains and Kaur J et al, have reported that only 4% of Klebsiella pneumoniae strains in their study were both ESBL and AmpC β-lactamase producers. Actually, it is difficult to detect ESBL if strain is Co-producers of ESBL and AmpC β-lactamase as AmpC β-lactamase mask the ESBL production. In that case if just combined disc CAZ/CAC is used for ESBL detection, ESBL may be missed. In the present study it was found that in ESBL and AmpC β- lactamase Co-producers strains a thin rim of growth around the edge of zone of inhibition was found in CAC or zone diameter of CAC was just >5mm more when compared to CAZ alone.

Table 2: Incidence of AmpC β-lactamase producing Klebsiella pneumoniae strains reported by various workers.

| Author | Years | Place of study | AmpC β-lactamase % |
|--------|-------|---------------|-------------------|
| Suranjana A. et al | 2005 | Kolkata, India | 13 |
| Gupta V, et al | 2012 | Chennai, India | 32 |
| Barua T, et al | 2013 | Muscat, Oman | 34.3 |
| Ranjini CY, et al | 2015 | Karnataka, India | 35.2 |
| Present study | 2016 | Wardha, India | 25 |
In the present study, in screening test, Cefotaxime (CTX), Ceftazidime (CAZ) and Cefpodoxime (CPD) were resistant to 142 (47.3%), 139 (46.3%) and 148 (49.3%) strains respectively while the total ESBL producing strains were 136 (45.3%). The reason for more resistant strains in screening test may be due to the mechanism other than ESBL production such as porin loss, efflux pump etc. The same may be the reason for more resistance to Cefoxitin (CX) and Cefotetan (CTN) i.e. 91 (30.3%) and 101 (33.7%) respectively in screening test of AmpC β-lactamases, as confirmatory tests detected only 75 (25%) strains. In the present study also, Cefoxitin (CX) was a better indicator than Cefotetan (CTN) as all 75 strains positive by confirmatory tests were resistant to Cefoxitin (CX). Four strains i.e. (4/75) were false negative by Cefotetan (CTN). Polfsuss et al, have also reported that Cefoxitin (CX) was a better indicator of AmpC β-lactamase production than Cefotetan. The studies from India showed a wide range of incidence of AmpC production by Enterobacteriaceae. Gupta et al in 2012 reported that 32% of their Klebsiella pneumoniae strains were AmpC producers. Ranjini et al, have reported 30.8% of Klebsiella spp isolated from diabetic foot were ESBL producers and 56.3% were AmpC β-lactamase producers. The studies from India showed a wide range of incidence of AmpC production by Enterobacteriaceae. Gupta et al, reported that 32% of their Klebsiella pneumoniae strains were AmpC producers. Ranjini et al, have reported 30.8% of Klebsiella spp. isolated from diabetic foot were ESBL producers and 56.3% were AmpC β-lactamase producers.

**CONCLUSION**

A total number of 300 Klebsiella pneumoniae strains were isolated from different clinical specimens like urine, blood, pus and wound swab etc. and were identified by conventional methods. It shows that 75 (25%) Klebsiella pneumoniae strains were positive for AmpC β-lactamases production either alone or in combinations with other β-lactamases. 75 strains were positive for AmpC β-lactamase (25%). These 75 strains were further confirmed by E Test (CN/CNI).

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

**REFERENCES**

1. Abraham EP, Chain E. An enzyme from bacteria able to destroy penicillin Nature. 1940;146:837.
2. Burman LG, Park JT, Lindström EB. Resistance of Escherichia coli to penicillins: identification of the structural gene for the chromosomal penicillinase. J. Bacteriol. 1973;116:123-30.
3. Knott-Hunziker V, Petursson S, Jayatilake GS. Active sites of β-lactamases. Biochem. J. 1982;201:621-7.
4. Ambler RP. The structure of β-lactamases. Phil. Trans. R.Soc. Lond. B. Biol. Sci. 1980;289:321-31.
5. Bush K, Jacoby GA, Medeiros A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33.
6. Philippon A, Arlet G, Jacoby GA. Plasmid determined AmpC type β-lactamases. Antimicrob Agents Chemother. 2002;46:1-11.
7. Praveen RM, Harish BN, Parija SC. AmpC Beta Lactamases among Gram Negative Clinical Isolates from Tertiary Hospital, South India. Brazilian Journal of Microbiology. 2010;41:596-602.
8. Washington CW, Stephen DA, Williams MJ, Elmer WK, Gary WP, Paul CS, et al. Antimicrobial susceptibility testing. in chapter 17. Koneman’s Color Atlas and Textbook of Diagnostic Microbiology, 6th Ed, Lippincott Williams & Wilkins, Philadelphia, USA; 2006;945-1021.
9. Polfsuss S, Bloemberg GV, Giger J, Meyer V, Böttger EC, Hombach M. Practical approach for reliable detection of AmpC beta-lactamase-producing Enterobacteriaceae. Journal of clinical microbiology. 2011 Aug 1;49(8):2798-803.
10. Manchanda V, Singh NP. Occurrence and detection of AmpC β-lactamases among Gram negative clinical isolates using a modified three-dimensional tests at Guru Tegh Bahadur Hospital Delhi, Indian J. Antimicrobe Chemother. 2003;51:415-8.
11. Black JA, Moland ES, Thomson KS. AmpC disc test for detection of plasmid mediated AmpC β-lactamases in Enterobacteriacea lacking chromosomal AmpC β-lactamases. J Clin Micro. 2005;43:3110-3.
12. Yagi T, Wachino JI, Kurokawa H, Suzuki S, Yamane K, Doi Y, et al. Practical methods using boronic acid compounds for identification of class C β-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Journal of Clin Mic. 2005 Jun 1;43(6):2551-8.
13. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J of Clin Micr. 2002 Jun 1;40(6):2153-62.
14. Bauer AW, Kirby WMM, Sherris JC, Turk J. Antibiotic susceptibility testing by standardised single disc method. Am. J. Clin Pathol. 1966;45:493-6.
15. Carter MW, Oakton KJ, Warner M, Livermore DM. Detection of extended spectrum beta lactamase in Klebsiella with the oxoid combination disc method. J Clin Microbiol. 2000;38:4228-32.
16. Coudron PE. Inhibitor based methods for detection of plasmid mediated AmpC β lactamases in Klebsiella spp., Escherichia coli and Proteus mirabilis. J. Clin. Microbiol. 2005;43:4163-7.
17. Philippon A, Arlet G, Jacoby GA. Plasmid determined AmpC type β-lactamases. Antimicrob Agents Chemother. 2002;46:1-11.
18. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A Clinical Update. Clin. Microbiol. Rev. 2005;18(4):657-86.

19. Gupta V, Kumarasamy K, Gulati N, Garg R, Krishnan P, Chandra J. AmpC β-lactamases in nosocomial isolates of Klebsiella pneumoniae from India. Indian J Med Res. 2012;136:237-41.

20. Ranjini CY, Rangasamy VR. Detection of ESBL and Plasmid-mediated AmpC β-lactamases among Gram-negative bacterial isolates in diabetic foot ulcer infections. Community Acquired Infections. 2015;2(2):57-62.

Cite this article as: Singh P. The incidence of AmpC β-lactamases producing Klebsiella pneumoniae subspecies pneumoniae. Int J Res Med Sci. 2018;6:1169-73.